Lipomics President a Guest Speaker at FDA’s Genomics and Proteomics Interest Group Meeting
News Oct 25, 2005
Lipomics Technologies, Inc. has announced that Steve Watkins, Ph.D., Lipomics founder, president, and chief scientific officer, was a guest speaker at the recent Genomics and Proteomics Interest Group meeting at the Food and Drug Administration (FDA).
Watkins’ presentation addressed metabolomics, focusing on small molecule metabolites that are proximal effectors of health and disease and hold considerable promise in many aspects of drug development and personalized medicine.
“The FDA is clearly thinking to the future by devoting a session of a group generally focused on genomics to the topic of metabolomics,” said Tom Anderson, Ph.D., Lipomics’ CEO.
“The FDA is looking ahead to applications of metabolomics in the drug development process and we are pleased that Steve was asked to provide the overview to this group.”
Chaired by Dr. Norris Alderson, the Associate Commissioner of Science at the FDA, this working group includes leading scientists at each of the seven centers of the FDA.
The Group meets periodically to enable FDA scientific leaders to stay current with the rapidly changing landscape of genomics and proteomics.
Analytical Tool Predicts Disease-Causing GenesNews
Predicting genes that can cause disease due to the production of truncated or altered proteins that take on a new or different function, rather than those that lose their function, is now possible thanks to an international team of researchers that has developed a new analytical tool to effectively and efficiently predict such candidate genes.
‘Good Cholesterol’ May Not Always be Good for Postmenopausal WomenNews
Postmenopausal factors may have an impact on the heart-protective qualities of high-density lipoproteins (HDL) – also known as ‘good cholesterol’ – according to a study led by researchers in the University of Pittsburgh Graduate School of Public Health.READ MORE
What Makes Good Brain Proteins Turn Bad?News
The protein FUS is implicated in two neurodegenerative diseases: amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD). Using a newly developed fruit fly model, researchers have zoomed in on the protein structure of FUS to gain more insight into how it causes neuronal toxicity and disease.